Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
68
RVMD Quote, Financials, Valuation and Earnings
Last price:
$81.20
Seasonality move
:
-4.35%
Day range:
$80.01 - $81.97
52-week range:
$29.17 - $81.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.83x
Volume:
1.4M
Avg. volume:
2.5M
1-year change:
82.9%
Market cap:
$15.7B
Revenue:
--
EPS (TTM):
-$5.18
Analysts' Opinion
-
Consensus RatingRevolution Medicines, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $83.26, Revolution Medicines, Inc. has an estimated upside of 2.55% from its current price of $81.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $72.00 representing 100% downside risk from its current price of $81.19.
Fair Value
-
According to the consensus of 16 analysts, Revolution Medicines, Inc. has 2.55% upside to fair value with a price target of $83.26 per share.
RVMD vs. S&P 500
-
Over the past 5 trading days, Revolution Medicines, Inc. has overperformed the S&P 500 by 4.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Revolution Medicines, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Revolution Medicines, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Revolution Medicines, Inc. reported revenues of --.
Earnings Growth
-
Revolution Medicines, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Revolution Medicines, Inc. reported earnings per share of -$1.61.
Enterprise value:
13.9B
EV / Invested capital:
7.93x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.35x
EV / Free cash flow:
-17.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$15.2M
Return On Assets:
-42.1%
Net Income Margin (TTM):
--
Return On Equity:
-51.27%
Return On Invested Capital:
-47.95%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $26.2M | $742K | -- | -- | -- | |
| Gross Profit | $17.1M | -$10.5M | -$15.2M | -$2.9M | -$4.3M | |
| Operating Income | -$368.9M | -$653.2M | -$1B | -$175.7M | -$315.3M | |
| EBITDA | -$359.9M | -$641.9M | -$1B | -$172.8M | -$310.9M | |
| Diluted EPS | -$3.26 | -$3.59 | -$5.18 | -$0.94 | -$1.61 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $623.5M | $675.1M | $824.5M | $1.6B | $2B | |
| Total Assets | $735M | $825.9M | $984.2M | $1.8B | $2.3B | |
| Current Liabilities | $51.9M | $73.3M | $85.5M | $110.9M | $245.6M | |
| Total Liabilities | $96.8M | $144.5M | $146.8M | $196.7M | $655M | |
| Total Equity | $638.2M | $681.4M | $837.5M | $1.6B | $1.6B | |
| Total Debt | $26.8M | $58.2M | $57.1M | $78.3M | $142.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$291.8M | -$539.7M | -$761.8M | -$130.4M | -$207.3M | |
| Cash From Investing | $30.7M | -$541.9M | -$349.7M | -$21.5M | $24.8M | |
| Cash From Financing | $441.2M | $925M | $1.1B | $77.3M | -$1.6M | |
| Free Cash Flow | -$300.1M | -$551.1M | -$777.1M | -$133.9M | -$210.7M | |
RVMD
Sector
Market Cap
$15.7B
$28M
Price % of 52-Week High
99.05%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-10.15%
-1.54%
1-Year Price Total Return
82.9%
-17.48%
Beta (5-Year)
0.959
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$78.76
200-day SMA
Buy
Level
$46.50
Bollinger Bands (100)
Buy
Level
39.36 - 70.2
Chaikin Money Flow
Buy
Level
4.8M
20-day SMA
Buy
Level
$78.28
Relative Strength Index (RSI14)
Buy
Level
70.66
ADX Line
Buy
Level
15.11
Williams %R
Sell
Level
-8.6957
50-day SMA
Buy
Level
$68.09
MACD (12, 26)
Buy
Level
21.00
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
2.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.6144)
Buy
CA Score
(Annual)
Level (-0.083)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.5097)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, RVMD has received 16 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RVMD average analyst price target in the past 3 months is $83.26.
-
Where Will Revolution Medicines, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Revolution Medicines, Inc. share price will rise to $83.26 per share over the next 12 months.
-
What Do Analysts Say About Revolution Medicines, Inc.?
Analysts are divided on their view about Revolution Medicines, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Revolution Medicines, Inc. is a Sell and believe this share price will drop from its current level to $72.00.
-
What Is Revolution Medicines, Inc.'s Price Target?
The price target for Revolution Medicines, Inc. over the next 1-year time period is forecast to be $83.26 according to 16 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RVMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Revolution Medicines, Inc. is a Buy. 16 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RVMD?
You can purchase shares of Revolution Medicines, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Revolution Medicines, Inc. shares.
-
What Is The Revolution Medicines, Inc. Share Price Today?
Revolution Medicines, Inc. was last trading at $81.20 per share. This represents the most recent stock quote for Revolution Medicines, Inc.. Yesterday, Revolution Medicines, Inc. closed at $81.19 per share.
-
How To Buy Revolution Medicines, Inc. Stock Online?
In order to purchase Revolution Medicines, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RVMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RVMD
Sector
P/E ratio
--
23.89x
PEG ratio
-0.35x
-0.01x
P/B ratio
9.83x
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
RVMD
Sector
Revenue growth
--
4.62%
Earnings growth
-72.19%
10.88%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$1.41
-$0.21
Profitability
RVMD
Sector
Profitability FY 2024
-$11.8M
$3.5M
Return on invested capital
-47.95%
-31.77%
Return on assets
-42.1%
-27.96%
Return on equity
-51.27%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
4
Balance Sheet
RVMD
Sector
Total cash
$1.9B
$26.3M
Short term investments
$1.7B
$25.7M
Total assets
$2.6B
$78M
Long term debt
$142.1M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
